Table 2.
Effects of immunomodulatory drug-based maintenance therapy on progression-free survival and overall survival in multiple myeloma*
| Immunomodulatory drug | ASCT status | No. of trials | PFS | OS | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |||
| Thalidomide/Lenalidomide | combined | 18 | 0.62 (0.57 to 0.67) | <.001 | 0.93 (0.85 to 1.01) | .082 |
| with ASCT | 9 | 0.61 (0.54 to 0.68) | <.001 | 0.89 (0.73 to 1.07) | .214 | |
| without ASCT | 11 | 0.63 (0.55 to 0.71) | <.001 | 0.95 (0.88 to 1.04) | .273 | |
| Thalidomide | combined | 12 | 0.66 (0.61 to 0.72) | <.001 | 0.94 (0.85 to 1.05) | .278 |
| with ASCT | 6 | 0.67 (0.61 to 0.74) | <.001 | 0.90 (0.73 to 1.11) | .343 | |
| without ASCT | 7 | 0.66 (0.57 to 0.76) | <.001 | 0.97 (0.85 to 1.11) | .627 | |
| Lenalidomide | combined | 6 | 0.52 (0.44 to 0.62) | <.001 | 0.87 (0.73 to 1.04) | .135 |
| with ASCT | 3 | 0.49 (0.41 to 0.57) | <.001 | 0.82 (0.48 to 1.41) | .477 | |
| without ASCT | 4 | 0.55 (0.43 to 0.72) | <.001 | 0.95 (0.85 to 1.05) | .308 | |
* All statistical tests were two-sided. ASCT = autologous stem cell transplantation; CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; OS = overall survival.